rss
Br J Ophthalmol 2009;93:1396-1400 doi:10.1136/bjo.2009.157511
  • Original Article
  • Laboratory science

The effects of ranibizumab (Lucentis) on retinal function in isolated perfused vertebrate retina

  1. M Lüke1,
  2. K Januschowski2,
  3. J Lüke1,
  4. S Peters1,
  5. N Wirtz1,
  6. E Yörük2,
  7. C Lüke3,
  8. K U Bartz-Schmidt2,
  9. S Grisanti1,
  10. P Szurman2
  1. 1
    University Eye Hospital, University of Lübeck, Lübeck, Germany
  2. 2
    University Eye Hospital, Centre for Ophthalmology, Eberhard-Karls University of Tübingen, Tübingen, Germany
  3. 3
    Center of Ophthalmology, University of Cologne, Cologne, Germany
  1. Correspondence to Dr M Lüke, Eye Hospital, University of Lübeck, Ratzeburger Allee 160, D-23538 Lübeck, Germany; matthias.lueke{at}uk-sh.de
  • Accepted 20 May 2009
  • Published Online First 23 July 2009

Abstract

Background: Intraocular ranibizumab (Lucentis, Novartis, Basel Switzerland) is the primary choice in the treatment of neovascular age-related macular degeneration (AMD). Vascular endothelial growth factor (VEGF) is known to be a survival factor for neuronal cells. Therefore, blockage of all VEGF isoforms by ranibizumab could induce retinal dysfunction.

Methods: Using isolated bovine retinas, the electroretinogram (ERG) was recorded as a transretinal potential using Ag/AgCl electrodes, while the retinas were perfused with an oxygen preincubated nutrient solution. For 45 min, ranibizumab was applied at a concentration of 0.2 mg/ml and alternatively the solvent carrier without the active agent. The ERG was monitored before, during and after exposure.

Results: The concentration of 0.2 mg/ml ranibizumab induced a non-significant b-wave reduction of 22.32% after exposure (p = 0.13). For the a-wave amplitude only a reduction of 4% was detected (p = 0.18). The solvent carrier induced no significant reduction of the a- and b-wave amplitudes (p = 0.30 and p = 0.979, respectively).

Conclusion: In the ex vivo model, the isolated perfused vertebrate retina, ranibizumab has been proven to be a safe compound at the concentrations applied. The stability of the ERG-amplitudes rules out a considerable retinal dysfunction after an injection of up to 1 mg ranibizumab.

Footnotes

  • Funding This study has been funded by Novartis (Basel, Switzerland).

  • Competing interests None.

  • Provenance and Peer review Not commissioned; externally peer reviewed.

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. All versions of this article:
    1. bjo.2009.157511v1
    2. 93/10/1396 most recent

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.